Multidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022

  19 December 2022

The Netherlands is a country with a low prevalence of multidrug-resistant organisms (MDRO), including carbapenemase-producing Enterobacterales (CPE), carbapenemase-producing  (CPPA), carbapenem-resistant  complex (CRAB) and meticillin-resistant  (MRSA) [14]. Active MDRO screening and infection prevention measures (e.g. isolation of suspected colonised patients) applies to all patients admitted to a Dutch hospital who have recently been admitted to a hospital abroad (< 2 months ago for > 24 h) or resided in a centre for asylum seekers. Since March 2022, there has been an emergence of MDRO in the Netherlands in persons originating from Ukraine. Persons from whom isolates were obtained were receiving hospital care in the Netherlands and are henceforth referred to as patients. Here, we describe the epidemiology and genetic analysis of MDRO from patients from Ukraine in the Netherlands.

Further reading: Eurosurveillance
Author(s): Romy D Zwittink et al
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!